Cannabidiol
- Generic Name
- Cannabidiol
- Brand Names
- Epidiolex, Sativex, Epidyolex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 13956-29-1
- Unique Ingredient Identifier
- 19GBJ60SN5
- Background
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...
- Indication
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...
- Associated Conditions
- Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain
- Associated Therapies
- -
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 150
- Registration Number
- NCT02088060
- Locations
- 🇩🇪
Department of General Psychiatry, Heidelberg University, Heidelberg, BW, Germany
🇩🇪Dept. of Psychiatry and Psychotherapy, Technical University Munich, Munich, BY, Germany
🇩🇪Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, BW, Germany
Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 5
- Registration Number
- NCT02083874
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
- Conditions
- Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung CancerRenal Cell CarcinomaMesotheliomaSuccinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal TumorsTumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 MutationsFumarate Hydratase (FH)-Deficient TumorsSuccinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)Tumors Harboring Amplifications in the cMyc Gene
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 210
- Registration Number
- NCT02071862
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 74
- Registration Number
- NCT02051387
- Locations
- 🇩🇪
Dept. of Pharmacology, University of Cologne, Cologne, NRW, Germany
🇩🇪Central Institute of Mental Health, Mannheim, BW, Germany
Cannabidiol: a Novel Intervention for Cannabis Use Problems?
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- University College, London
- Target Recruit Count
- 82
- Registration Number
- NCT02044809
- Locations
- 🇬🇧
Clinical Psychopharmacology Unit, London, United Kingdom
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 50
- Registration Number
- NCT01844687
- Locations
- 🇺🇸
Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120, New York, New York, United States
🇺🇸Center for Drug and Alcohol Programs, Room 459 North, 67 President St., Charleston, South Carolina, United States
🇺🇸University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct., Lexington, Kentucky, United States
Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01596075
- Locations
- 🇮🇱
Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel
Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse
- First Posted Date
- 2011-03-10
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Hurd,Yasmin, Ph.D.
- Target Recruit Count
- 18
- Registration Number
- NCT01311778
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
The Effects of Cannabidiol and ∆-9-THC in Humans
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 27
- Registration Number
- NCT01180374
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Cannabidiol for Inflammatory Bowel Disease
- Conditions
- Interventions
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Meir Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01037322
- Locations
- 🇮🇱
Sapir Medical center Meir Hospital, Kefar Saba, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.